The biosimilar recombinant human G-CSF (rhG-CSF), possessing a similar biological mechanism, has been successfully approved for application in reducing the risk and duration of chemotherapy-induced neutropenia and febrile neutropenia [12, 13]. This evidence concerns the gene CSF3 and Decreased total neutrophil count.